Glioblastoma multiforme represents the most aggressive of all primary brain neoplasms in adults, characterized by extremely poor prognosis and limited therapeutic interventions. This paper reviews current knowledge regarding molecular and histopathological insights into GBM. Besides demonstrating necrosis and microvascular proliferation with high cellularity- which have made it a diagnosis of classification and clinical behavior- at the molecular level this tumor is unleashed by diverse genetic and epigenetic changes. This includes alterations in IDH mutation, PTEN loss, EGFR amplification as well as MGMT promoter methylation controlling tumor progression as well as treatment response to therapies. Further, therapeutic resistance arising due to the heterogeneity of cells within tumors plus associated recurrence has emphasized another dimension requiring focus in research studies regarding treatment options for cancer anywhere between baseline laboratory benches up through human patient applications. Additionally included are immune cell components among others such as extracellular matrix elements plus signaling pathways promoting invasion/survival processes inside mass development regions resulting finally to Spatial Transcriptomics-based single-cell sequencing mapping out spatial complexity yet providing directions towards potential biomarkers along with precise therapy choices. Progress does not dissuade the fact that GBM carries such a forlorn prognosis, hence the need for integrated research approaches that would incorporate histological, molecular, and microenvironmental information. It is, therefore, imperative to underscore comprehensive tumor profiling in guiding future therapeutic strategies toward clinical outcome improvement.
Al-Taee et al. (Mon,) studied this question.